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This paper is an attempt to evaluate the anti-inﬂammatory and analgesic activities and the possible mechanism of action of tender
leaf extracts of Shorea robusta, traditionally used in ailments related to inﬂammation. The acetic-acid-induced writhing and tail
ﬂick tests were carried out for analgesic activity, while the anti-inﬂammatory activity was evaluated in carrageenan-and dextran-
induced paw edema and cotton-pellet-induced granuloma model. The acetic-acid-induced vascular permeability, erythrocyte
membrane stabilization, release of proinﬂammatory mediators (nitric oxide and prostaglandin E2), and cytokines (tumor necrosis
factor-α, and interleukins-1β and -6) from lipopolysaccharide-stimulated human monocytic cell lines were assessed to understand
the mechanism of action. The results revealed that both aqueous and methanol extract (400mg/kg) caused signiﬁcant reduction
of writhing and tail ﬂick, paw edema, granuloma tissue formation (P<0.01), vascular permeability, and membrane stabilization.
Interestingly, the aqueous extract at 40μg/mL signiﬁcantly inhibited the production of NO and release of PGE2,T N F - α,I L - 1 β,
and IL-6. Chemically the extract contains ﬂavonoids and triterpenes and toxicity study showed that the extract is safe. Thus, our
study validated the scientiﬁc rationale of ethnomedicinal use of S. robusta and unveils its mechanism of action. However, chronic
toxicological studies with active constituents are needed before its use.
1.Introduction
Inﬂammation is a complex biological response of vascular
tissues to harmful stimuli as well as a protective attempt
to remove the stimuli and initiate the healing process.
Inﬂammation has been classiﬁed as acute or chronic. Acute
inﬂammation is the initial response of our body to the
harmful stimuli, achieved by the increased movement of
plasma and granulocytes from blood to the injured tis-
sues [1]. A cascade of biochemical events involving the
vascular system, immune system, and various cells of the
injured tissue propagates and matures the response [2].
The aﬀected cells are then activated to release several
mediators (eicosanoids, cytokines, chemokines) at the site,
which elicit the inﬂammatory response from acute to the
chronic phase. In prolonged or chronic inﬂammation a
progressive shift of injured cells occurs at site and caused
simultaneous destruction and healing of the injured tissues
[3], during Which the release of cyclooxigenase (COX)-
mediated prostaglandins leads to pain, oedema, and fever.
Thus, COX inhibitors are used as antiinﬂammatory drugs.
However, many COX inhibitors produce serious adverse
eﬀects [4] and conventional nonsteroidal antiinﬂammatory
drugs are unsuitable for the management of chronic and
silent inﬂammations. Moreover, most of the modern anti-
inﬂammatory and analgesic drugs are synthetic, costly, and2 Evidence-Based Complementary and Alternative Medicine
have several side eﬀects like nephrotoxicity, respiratory prob-
lem, constipation, physical dependence, and gastrointestinal
irritation in long run. It is therefore essential to search
for cost eﬀective antiinﬂammatory agents with low toxicity
and better tolerance from ethnomedicinal source. As the
ethnomedicinalplants,inparticular,areanimportantsource
of drugs and candidate therapeutics [5, 6], their scientiﬁc
evaluation may provide new drug molecule to combat long-
term toxicity and cost.
The Indian ethnomedicine Shorea robusta L. (Diptero-
carpaceae), popularly known as Sal or Shal, is widely used in
AyurvedaandUnanimedicine.Theresinisusedasastringent
and detergent, in diarrhoea, dysentery, and gonorrhoea [7];
With Bee wax its act as an ointment base for foot cracks,
psoriasis, wounds, ulcers, burns, chronic skin diseases, and
ear and eye troubles [8];while seeds are used for pus forming
wounds [9]. A combination of oleoresin with cow ghee
is claimed to control burning sensation of haemorrhoids,
pain, and swelling [10]. A recent study with methanol
extract of mature leaves reported anti-inﬂammatory and
antinociceptive activity [11]. However, till date there is no
consistent scientiﬁc evidence of those claims with aqueous
extract used in ethnomedicinal practice, and its in vitro and
in vivo mechanism of action. Therefore, for the ﬁrst time,
we have evaluated the eﬀect of both aqueous and methanol
extracts of S. robusta young tender leaves in several in vivo
and in vitro models. The generation of proinﬂammatory
mediators (prostaglandins and nitric oxide) and release of
proinﬂammatorycytokine(TNF-α,IL-1β,andIL-6)wasalso
studied as markers, to understand the possible mechanism of
action of this ethnomedicine used in traditional health care.
2.MaterialsandMethods
2.1. Plant Material. The young tender leaves of S. robusta
L. were collected in April, August and December 2008 and
2009,fromthenearbyforestoftribalareatoruleoutpossible
seasonal variation of chemical content of the specimen. The
identiﬁcation and authentication was done by a Taxonomist
of the Botanical Survey of India, Shibpur, Howrah, and
voucher specimen (Herbarium No. 07/08/17775) has been
deposited at the Herbarium and at the host Institute.
2.2. Preparation of Samples and Studies on Their Physico-
chemical Properties. Following strict standards, the collected
part was washed thoroughly, dried in shade, pulverized by
a mechanical grinder, and passed through 40-mesh sieve to
get the ﬁne powder. The physicochemical characters (total
ash,acidinsolubleash,andwatercontent)andthebehaviour
of powdered sample dissolved in diﬀerent chemicals and
exposed to visible and UV (312nm) light [12] were studied
for constant quality and better yield [13].
2.3. Extraction and Physicochemical Standardization of Ex-
tracts. Five hundred grams of powdered young leaves was
extracted with distilled water (2.5L) and 95% methanol
(2L) separately, with maceration upto 48–72h at room
temperature [14]. The extract was repeatedly ﬁltered and
centrifuged (800 ×g for 10min) to remove the impurities.
The collected aqueous extract was lyophilized, while the
methanol extract was evaporated to dryness under reduced
pressure at 40–45◦C to yield crude extract (55.5g). The %
rendement or yield (w/w) of the extracts was determined
by standard formula: % yield (w/w) = ﬁxed weights of the
extract/Sample weight ×100.
2.4. Isolation of Fractions from Aqueous Extract. The afore-
mentioned crude extract (50g) was subjected to phytochem-
ical group tests of tannin (with 10% potassium dichro-
mate/lead acetate/5% ferric chloride), reducing sugar (Bene-
dict’s and Fehling’s tests), steroids (Libermann-Burchard
test), terpenoids (Salkowski test), ﬂavonoids (extract was
hydrolyzed with 10% sulphuric acid, extracted with diethyl
ether and divided into three parts to test with sodium
carbonate, sodium hydroxide and ammonium solution) and
others, following standard methods [15, 16]. The aqueous
extract was then extracted with ethyl acetate (7 × 1L)and
concentrated under reduced pressure to yield a dark brown
liquid mass of 1.5g. The residual material was puriﬁed
on Silica gel Column using hexane and ethyl acetate as
eluent to collect six distinct fractions (F1 to F6), which were
monitored by TLC [17]. The yield of fractions 1 to 6 was:
40mg,30mg,20mg,60mg,80mg,and250mg,respectively.
For chromatography, the precoated HPTLC silica gel
plate (60 F254 of 0.2mm thickness and 20×10cm size, Merck
KGaA, Germany) was used. One mg/mL stock solutions of
extracts were prepared in water and methanol separately.
Then 100μL of each isolated fraction (1–6) was loaded on
HPTLC plates at 20mm distance, using a Linomat IV spotter
(Camag, Pvt. Ltd., Switzerland). Plates were dried and
developed by ethylacetate:methanol (9:1) solvent system,
and further dried to observe under visible and UV (254nm)
light, and scanned by a Camag Scanner III (Switzerland).
The signiﬁcant biological activity demonstrated by the
aqueous extract intended us to further investigate the pres-
ence of plausible phytoconstituents, which may be responsi-
ble for such potential activities. Therefore, the water extracts
were further subjected for puriﬁcation and chromatographic
fractionation.
2.5. Animals. Healthy Swiss albino male mice (18–20g), and
adultmaleWistarrats(150–180g)werehousedintheanimal
house facility of the Department of Pharmaceutical Technol-
ogy,JadavpurUniversity,Kolkata,andmaintained(23±4◦C,
relative humidity 60–70%) on a standard diet with water ad
libitum. The animals were acclimatized for two weeks before
the experiments. All animal experiments were carried out in
accordancewiththeapproval(APRO/69/20/08/09;Dated20-
08-2009) and guidelines of the Institutional Animal Ethics
Committee.
2.6. Chemicals and Drugs. Dimethylsulfoxide (DMSO),
carrageenan, phorbol-12-myristate-13-acetate (PMA), dex-
amethasone, NS-398 (N-[2-(cyclohexyloxy)-4-nitrophenyl]-
methanesulfonamide), and lipopolysaccharide (LPS) of E.
coli 026:B6 were purchased from Sigma-Aldrich (St. Louis,Evidence-Based Complementary and Alternative Medicine 3
Mo, USA). The L-NIL (N6-(-iminoethyl)-L-lysine, dihy-
drochloride) was obtained from Santa Cruz Biotechnology,
Inc., USA; while RPMI 1640, fetal bovine serum (FBS),
penicillin and streptomycin, trypsin-EDTA, and Tris-buﬀer
were purchased from Gibco-BRL (Karlsruhe, Germany). The
commercial enzyme linked immunosorbent assay (ELISA)
kit for TNF-α and PGE2 was purchased from the BD
Biosciences, New Jersey, USA, while IL-1β and IL-6 from
the R&D System, Minneapolis, MN, USA, respectively.
The Griess reagent, dextran, paracetamol, morphine sulfate,
diclofenac disodium, and indomethacin were purchased
from the respective manufacturers.
2.7. Acute Toxicity Study. The acute toxicity of S. robusta
extracts (aqueous and methanol) was evaluated on diﬀerent
groups of mice and male Wister rats at increasing doses
to determine the LD50. The animals were divided into ten
groups (n = 6) and extracts were administered orally (p.o)a t
a dose of 0–2500mg/kg, or by intraperitoneal (i.p.) injection
at 0–1000mg/kg. The animals were observed periodically (6,
12, 18 and 24h) for symptoms of toxicity and death and then
daily for next 14 days [18]. No acute toxic eﬀects (agility,
muscular tonus, tremors, convulsions, problem in breathing,
water or food intake) or mortality was observed following
treatment, so the procedure was repeated up to the highest
dose of 3.5gm/kg p.o. The dose regimen of the test extracts
was selected (200 and 400mg/kg) on the basis of the acute
toxicity data.
2.8. Analgesic Activity
2.8.1. Acetic Acid-Induced Writhing Tests. This was per-
formed following a modiﬁed method of Koster and Ander-
son [19]. Brieﬂy, Swiss albino mice of either sex (18–20g)
were separately divided into six groups of six animals each.
The ﬁrst group served as control; the second group was
administered with paracetamol (50mg/kg), while the third
to sixth groups received aqueous and alcoholic extract of
S. robusta, at doses of 200 and 400mg/kg as i.p. injection.
After 30min of drug treatment, the animals were given 1%
v/v acetic acid solution at 10mL/kg i.p. immediately after
5 minutes of acetic acid administration and the numbers
of writhing or stretches (a syndrome, characterized by a
wave of contraction of the abdominal musculature followed
by extension of hind limbs) were counted for 15 minutes.
A reduction in the writhing number compared to the
control group was considered as the analgesia [15]. The
percentageinhibitionofwrithingwascalculatedaccordingto
the following formula: % Inhibition = C−T/C×100, Where
C is the mean number of writhes produced by the control
group and T is the mean number of writhes produced by the
test groups.
2.8.2. Tail Flick Test. Swiss albino mice of either sex (18–
20g) were divided into six groups (n = 6). The tail of
each mouse was placed on the nichrome wire of an anal-
gesiometer (Techno Lab, Lucknow, India) and the time
taken by the animal to withdraw (ﬂick) its tail from the
hot wire was taken as a reaction time. The aqueous and
alcoholic extract of S. robusta at doses of 200 and 400mg/kg
were injected i.p., using Morphine sulphate (5mg/kg) as
standard drug. Analgesic activity was measured after 30min
of administration of extract and drug [15, 20] and the
percentage inhibition was calculated by the aforementioned
formula.
2.9. Antiinﬂammatory Activity
2.9.1. Carrageenan-Induced Rat Paw Oedema (Acute Model).
Inﬂammation in the hind paw of Wistar albino rats was
induced by the method of Winter et al. [21]. Animals were
divided into six groups (n = 6). First four groups of animals
were pretreated with the aqueous and alcoholic extract at
dosesof200and400mg/kgi.p.,1hpriortosubplantar(right
hind paw) injection of 0.1mL of 1% (w/v) fresh carrageenan
in normal saline. The 5th group serves as vehicle control,
while the 6thgroup received diclofenac disodium (10mg/kg)
as positive control. The edema volume (linear circumference
of the injected paw) was measured by a plethysmometer at
0h and 1h interval upto 5h after carrageenan injection [22].
The antiinﬂammatory activity was evaluated based on the
ratio of the changes in paw diameter in treated and untreated
group as per the formula: anti-inﬂammatory activity (%) =
(1 − D/C) × 100, where D is the change in paw diameter
in treated group and C is the change in paw diameter in
untreated group.
2.9.2. Dextran-Induced Rat Paw Oedema (Subacute Model).
The hind paw edema on the right foot of a rat was induced
by subplantar injection of 0.1mL of freshly prepared 1%
dextran solution [23]. Paw volumes were measured 30min
before and after dextran injection. The treatment of extracts
(test), vehicle (vehicle control), and standard drug (drug
control) was the same as described for carrageenan model.
The percentage inhibition of edema was calculated by the
method of Kavimani et al. [24].
2.9.3. Cotton-Pellet-Induced Granuloma (Chronic Model).
The rats were divided into six groups (n = 6) and were
anaesthetized after shaving of the fur. Sterile preweighed
cotton pellets (10mg) were implanted in the axilla region of
each rat through a single needle incision [25]. Aqueous and
methanol extracts at 200 and 400mg/kg were administered
i.p. 60min before the cotton pellet implementation to
the ﬁrst four groups. The ﬁfth group served as vehicle
control, and the sixth group received diclofenac disodium
(10mg/kg), for consecutive seven days from the day of
beginning of implantation. On eighth day, the animals were
anaesthetized; the cotton pellets were removed surgically
and made free from extraneous tissues. To obtain constant
weight, the pellets were incubated at 37◦C for 24h and dried
at 60◦C. The granuloma weight was calculated by measuring
the increase in dry weight of the pellets of the treated and
control groups.4 Evidence-Based Complementary and Alternative Medicine
2.10. Acetic-Acid-Induced Vascular Permeability in Mice. The
vascular permeability in mice was tested by the method of
Whittle [26] with modiﬁcations. Brieﬂy, randomly selected
mice, each with six animals, were divided into six groups.
Group I served as vehicle control, groups II to V were treated
with 200 and 400mg/kg of aqueous and alcoholic extract,
while group VI received indomethacin (10mg/kg) orally.
One hour after the treatment, 200μLo f0 . 2 %E v a n ’ sb l u ei n
normal saline was injected through tail vein of each mouse
(at 0.2mL/20gm body weight). Thirty minutes later, the
acetic acid (0.6%) in normal saline (0.2mL) was injected
i.p. to each mouse. After 1h, the mice were sacriﬁced and
the abdomen was open to expose the entrails and washed
with normal saline (5mL) to collect the content in a test
tube. The content was centrifuged and the absorbance of
the supernatant was measured in a spectrophotometer at
500nm. The vascular permeability eﬀects were expressed as
the absorbance (A) of the amount of dye leaked into the
intraperitoneal cavity.
2.11. Membrane Stabilizing Activity. Membrane stabilizing
activity of the extract was assessed by hypotonic solution-
induced human erythrocyte haemolysis [27]. Whole blood
was collected from a healthy volunteer (DC) in a heparinized
tube and washed thrice with isotonic buﬀer (154mM
NaCl in 10mM sodium phosphate buﬀer, pH 7.4) for 10
minutes at 3000g. The RBC suspension (0.5mL) mixed
with 5mL of hypotonic solution (50mM N aCl in 10mM
PBS, pH 7.4) with or without the extract (0.15–3.0mg/mL)
or indomethacin (0.1mg/mL) in triplicate was incubated
(10min at room temperature) and centrifuged (3000g for
10min), and the absorbance of the supernatant was mea-
sured at A590 nm. The percentage inhibition of haemolysis
was calculated according to the formula: % Inhibition of
haemolysis = 100 ×{ OD1 − OD2/OD1},w h e r eO D 1 is the
Optical density of hypotonic buﬀered saline solution alone,
and OD2 is the optical density of test sample in hypotonic
solution.
2.12. In Vitro Assay of PGE2,T N F - α, and Nitric Oxide in
LPS-Induced THP-1 Cell. Human monocytic THP-1 cells
obtained from the National Centre for Cell Science, Pune,
India, were grown at 37◦C in RPMI 1640 containing
heat inactivated FBS (10%), penicillin (100IU/mL) and
streptomycin (100μg/mL) at 37◦Ci n5 %C O 2 atmosphere.
Cells at the exponential growth phase were trypsinized and
suspended in complete medium at 5 × 105 cells/mL [28].
Cell suspension (500nm) was then activated with PMA
(100ng/mL) for 48h to obtain transformed macrophages.
Cell viability was checked by MTT assay and cytotoxicity
of the extract was evaluated in presence or absence of LPS.
The transformed cells were incubated with 100μLo fe x t r a c t s
(0–100μg/mL), or dexamethasone (1μM) for TNF-α,C O X -
2 inhibitor N-[2-(cyclohexyloxy)-4-nitrophenyl]-methanes-
ulfonamide, or NS-398 (10μM) for PGE2 as drug control
and0.5%DMSOasvehiclecontrol,respectively.After30min
of pretreatment cells were further incubated with 1μg/mL
LPS for 24h, and cell-free supernatants were collected to
determinePGE2 andTNF-αlevelbyEIAkits(BDBioscience,
USA) as per manufacturer’s instructions.
For measuring nitrite accumulation, an indicator of NO
synthesis, 100μL of the previous culture was mixed with
100μL of Griess reagent (equal volumes of 1% (w/v) sulfa-
nilamide in 5% (v/v) phosphoric acid and 0.1% (w/v) naph-
thylethylenediamine-HCl) and incubated at room temper-
ature for 10min. The selective inhibitor of inducible nitric
oxide synthetase N6-(1-iminoethyl)-L-lysine, dihydrochlo-
ride or L-NIL (10μM) was used as positive control. The
absorbance was measured at 550nm in microplate reader
using fresh culture media as blank. The amount of nitrite in
the sample was calculated from a standard curve prepared
with fresh sodium nitrite [29].
2.13. Determination of IL-1β and IL-6 Production. IL-1β and
IL-6 levels in macrophage culture media were quantiﬁed by
enzyme immunoassay kits (R&D System, Minneapolis, MN,
USA) according to the manufacturer’s instructions.
3.StatisticalAnalysis
The results were expressed as mean, mean ± SEM (Standard
Error Mean), and SD (Standard Deviation). The statistical
signiﬁcance was analyzed by Student’s t-test for unpaired
observationscomparedwiththecontrol,andthesigniﬁcance
of diﬀerence among the various test and control group was
analyzed by one-way ANNOVA followed by Dunnett’s t-test.
4. Results
In this study anti-inﬂammatory and analgesic potential of
aqueous and alcohol extracts of S. robusta young leaves
was evaluated by diﬀerent in vivo screening methods, along
with the mechanism of action of the most active extract.
To ﬁnd out the mechanism of action, the generation of
proinﬂammatory mediators like NO and PGE2 and release
ofcytokineslikeTNF-α,IL-1β,andIL-6fromPMA-activated
and LPS-stimulated THP-1 cells were measured.
4.1. Physicochemical and Phytochemical Group Tests and
Chromatographic Analysis. The physicochemical study, pre-
sented in Table 1 indicated that S. robusta young leaves
collected in August had maximum yield but minimum
water (23.69%), total ash (3.55 ± 0.45) and acid insoluble
ash (0.20 ± 0.3) content, compared to other samples. The
ﬂuorescence studies of the powdered samples made from
the leaf collected in August showed pale yellow to yellow
colour under visible and UV (312nm) light, while with
HCl, H2SO4, and HNO3, the colour was light to deep
brown, reddish brown, and orange, respectively. However
withaceticacid,chloroform,andn-hexane,thecolourvaried
from yellow green, yellow to pale yellow, and greenish
yellow and brown, respectively. The chemical group tests
and preliminary HPTLC analysis (Rf value, percentage area,
and λ max) of the extracts, presented in Table 2, showed
that both extracts had two bands with best resolution, whenEvidence-Based Complementary and Alternative Medicine 5
Table 1: The physicochemical properties of S. robusta young leave.
Sample Sample (in gm) Extract (in gm) %r e n d e m e n t
(yield)
Ash content
(% w/w)
Acid insoluble
ash (% w/w)
Water content
(%)
S. robusta (Aug) 500.00 50.5 10.1 ±0.51 3.55 ±0.45 0.20 ±0.30 23.69 ±12.51
S. robusta (Dec) 552.80 48.9 8.84 ±0.47 5.36 ±0.39 0.35 ±0.60 26.18 ±14.47
S. robusta (April) 508.50 42.3 8.31 ±0.41 6.23 ±0.27 0.42 ±0.17 26.56 ±0.56
Table 2: HPTLC and phytochemical analysis of extracts.
Sample Solvent system Chromatophore (s) Rf Area % λ max Phytochemical group
S. robusta extract Ethyl acetate:Methanol
(9:1)
Aqueous 1 0.78 19.33 104.3 Tannin, reducing sugar,
ﬂavonoids, Steroids Aqueous 2 0.87 41.93 155.4
Methanol 1 0.78 19.33 104.3 Tannin, ﬂavonoids, steroids,
terpenoids Methanol 2 0.87 41.33 155.4
Quercetin Ethylacetate:Methanol
(9:1)
Aqueous Q1 0.79 19.34 104.5 Flavonoid
Methanol Q1 0.81 19.55 105.1
Table 3: Analgesic activity by acetic-acid-induced writhing and tail ﬂick methods.
Treatment Dose (mg/kg) Writhing reﬂex
(Reaction time in sec) % Inhibition Tail ﬂick
(Reaction time in sec) % Inhibition
Control 15.00 ±0.40 0 22.22 ±0.56 0
Paracetamol 50 3 ±0.365
∗ 80 — —
Morphine 5 — — 5.20 ±0.10
∗ 76.59
S. robusta aqueous extract 200 5.5 ±0.763
∗ 63.33 7.68 ±0.27
∗ 65.43
400 4.33 ±0.421
∗ 71.13 6.6 ±0.15
∗ 70.29
S. robusta methanol extract 200 6 ±0.516
∗ 60.00 8.14 ±0.51
∗ 63.36
400 5 ±0.365
∗ 66.66 7.46 ±1.00
∗ 66.42
R e s u l t sa r ee x p r e s s e da sm e a n± SEM (n = 6), ∗P <0.001 compared to control (2% aqueous Tween 80v/v).
ethyl acetate:methanol = 9:1 was used as solvent. The
detail HPTLC analyses of fractions 1–6 were presented in
Figures 1, 2,a n d3 using friedelin as reference compound.
The HPTLC analysis clearly reveals the signiﬁcant purity of
isolated fraction but absence of friedelin as one of the major
compound in the extract.
4.2. Acute Toxicity Study. Oral and i.p. treatment of aqueous
andmethanolextractsupto14daysshowednomanifestation
of toxic eﬀects (convulsion, ataxy, diarrhoea, or increased
diuresis) or death in treated animals, indicating that both
the extracts posses good safety proﬁle. However, the reduced
motor activity, ataxia, and hyperventilation were observed
in mice, but not in rats, at oral doses of 3500mg/kg. The
LD50 of the orally fed methanolic and aqueous extracts
of S. robusta was determined as 2.4gm/kg and 2.7gm/kg;
while it was 1.2gm/kg and 1.4gm/kg in i.p,r e s p e c t i v e l y .B y
comparingwiththetoxicity-ratingchart[30],theextractwas
classiﬁed as nontoxic. Hence, the dose for further study was
selected as 200 and 400mg/kg. Further in vivo toxicological
study for 21 days with aqueous extract upto 1200mg/kg
(p.o.) did not induce mortality or clinical toxicity or reveal
any histopathological changes in kidney, liver and spleen
(Figure 4).
4.3. Analgesic Activity
4.3.1. Eﬀect of Extracts on Acetic-Acid-Induced Writhing Test.
The results of acetic-acid-induced writhing test with aque-
ous and methanol extract in mice, presented in Table 3,
showed that the maximum inhibition of writhing reﬂexes
was 60% and 63.33% at 200mg/kg while 66.66% and
71.13% at 400mg/kg i.p. of methanol and aqueous extracts,
respectively. Thus, compared to the paracetamol-treated
group (80% inhibition), the aqueous extracts at 400mg/kg
have equally signiﬁcant (P<0.001) inhibition.
4.3.2. Eﬀect of Extracts on Tail Flick Test. The results of tail
ﬂick test revealed that the aqueous extract at 400mg/kg i.p.
doses had reaction time of 6.6sec (70.29% inhibition); but
with methanol extract it was 7.46sec (66.42% inhibition).
However, with 200mg/kg dose the reaction time was 7.68sec
and 8.14sec (65.43% and 63.36% inhibition) respectively.
Thus, a dose-dependent signiﬁcantly (P<0.001) higher
eﬀect was recorded with the aqueous extract (400mg/kg)6 Evidence-Based Complementary and Alternative Medicine
Table 4: Eﬀect of extracts on carrageenan- and dextran-induced paw edema.
Treatment Dose (mg/kg) Carrageenan induced
paw edema % Inhibition Dextran induced
paw edema % Inhibition
Control 0.1mL 2.1 ±0.05 — 2.86 ±0.01 —
Diclofenac disodium 10 0.51 ±0.005 75.71 0.68 ±0.014 76.22
Aqueous extract 200 0.97 ±0.006 53.80 1.18 ±0.010 58.74
400 0.73 ±0.008 65.23 0.88 ±0.010 69.23
Methanol extract 200 1.08 ±0.007 48.57 1.36 ±0.011 52.44
400 0.80 ±0.009 61.90 1.07 ±0.013 62.58
R e s u l t sa r ee x p r e s s e da sm e a n± SEM (n = 6). The signiﬁcance level in comparison to control values, P<0.001. Control aqueous Tween-80 solution (2%v/v).
0
20
40
60
80
100
0.56
0.54
0.52
0.5
0.48
0.46
0
200
400
600
800
(
a
.
u
.
)
(mm)
(Rf )
(a)
−0.14 0.06 0.26 0.46 0.66 0.86 1.06
0
50
100
150
200
250
300
AutoGenerated2 at 580 nm
(b)
Figure 1: The HPTLC spectrogram (Rf = 0.49) of the reference compound “friedelin”, used as marker compound to evaluate the isolated
fraction for comparative analysis.
compared to the Morphine sulfate (5.20sec, 76.59% inhibi-
tion) after 30min (Table 3).
4.4. Antiinﬂammatory Activity
4.4.1. Eﬀect of Extracts on Carrageenan-Induced Rat Paw
Oedema. The results of the antiinﬂammatory activity of
the aqueous and methanol extract of S. robusta against
carrageenan-induced paw oedema in rats showed that there
was a gradual increase in the edema volume in the control
group during the study period. However, both aqueous and
methanol extract at 400mg/kg p.o. produced a signiﬁcant
dose-dependent inhibition (61.90 and 65.23%, P>0.001)
of paw oedema, compared to Diclofenac disodium (75.71%
inhibition) after 3h of treatment (Table 4).
4.4.2. Eﬀect of Extracts on Dextran-Induced Paw Oedema.
In dextran-induced paw oedema model, the maximum
(69.23%) inhibition of edema swelling was noted with
400mg/kg p.o. aqueous extracts, which are nearly similar
to diclofenac disodium (76.22% inhibition at 10mg/kg after
3h), while the minimum (52.44%) inhibition was recorded
with 200mg/kg p.o. of methanol extract. All these data are
signiﬁcant (P<0.0001) with respect to the control group
(Table 4).
4.4.3. Eﬀect of Extracts on Cotton-Pellet-Induced Granuloma.
The results presented in Figure 5 showed that both the
extracts signiﬁcantly inhibited the granuloma weight in
a dose dependent manner. However, the aqueous extract
(400mg/kg p.o.) had signiﬁcantly (P<0.001) higher inhi-
bition (54.12%) of the dry weight of granuloma compared
to diclofenac disodium (57.48% at 10mg/kg; P<0.05). On
the otherhand, moderate-to-high inhibitions were recorded
with other doses of aqueous and methanol extract.
4.5. Inhibition of Acetic-Acid-Induced Vascular Permeability
in Mice. Eﬀects of aqueous and methanolic extract (200
and 400mg/kg, p.o.) and indomethacin (10mg/kg, p.o.)o n
acetic-acid-induced vascular permeability in mice, presented
in Figure 6, revealed that the extract inhibited the vascular
permeability by 30% to 54.16%. However, aqueous extract
(400mg/kg) signiﬁcantly (P<0.001) inhibited vascular
permeability (54.16%) compared with vehicle control and
indomethacin (60.83%) group.
4.6. Eﬀects of Extracts on Membrane Stabilizing Activity. The
aqueous and methanolic extracts at 0.15mg/mL doses mod-
erately (P<0.05) protect the erythrocyte membrane against
lysis induced by hypotonic saline, as it inhibits haemolysis by
39.72–42.46%. However, the aqueous extract at 0.3mg/mL
and indomethacin at 0.1mg/mL doses oﬀered better (P<
0.01) protection (54.79% and 63.69%) compared to the
blank (Figure 7).Evidence-Based Complementary and Alternative Medicine 7
Spot 1, 2: Friedelin (pink)
Spot 3, 4: Fraction 2
Spot 5, 6: Fraction 4
(a)
Spots 1–3: Friedelin (not visible)
Spot 4, 5: Fraction 1
Spot 6, 7: Fraction 3
Spot 8, 9: Fraction 5
(b)
−0.14 0.06 0.26 0.46 0.66 0.86 1.06
0
50
100
150
200
250
300
Fraction 1
(c)
0
50
100
150
200
250
300
350
400
−0.14 0.06 0.26 0.46 0.66 0.86 1.06
Fraction 2
(d)
0
50
100
150
200
250
300
−0.14 0.06 0.26 0.46 0.66 0.86 1.06
Fraction 3
(e)
0
50
100
150
200
250
300
350
−0.14 0.06 0.26 0.46 0.66 0.86 1.06
Fraction 5
(f)
Figure 2: The HPTLC(a) spot1, 2 (pink)is marker compound friedelin, spot3, 4 is fraction 2, spot 5, 6 isfraction 4. (b)spot1–3 isfriedelin
(not visible), spot 4, 5 is fraction 1, spot 6, 7 is fraction 3 and spot 8, 9 is fraction 5.
4.7. Eﬀects of Extracts on Cell Viability, LPS-Induced NO2,
PGE2 and TNF-α Production. Cytotoxic eﬀect of both aque-
ous and methanol extracts was evaluated in presence or
absence of LPS and found that the cell viability was not
aﬀected by any of the extract upto 100μg/mL concentration.
The eﬀect of the extract on the production of NO, PGE2,
and TNF-α in the supernatant of PMA-activated and then
extract-treated and LPS-stimulated THP-1 cells was shown
in Figures 8(a), 8(b),a n d8(c). The LPS (1μg/mL) induced
increased NO2-production was signiﬁcantly suppressed by
positive inhibitor L-NIL (10μM); while both the extract
showed concentration-dependent inhibitory eﬀect on LPS-
induced NO production at noncytotoxic concentrations.
However, the aqueous extract was most active. Additionally,8 Evidence-Based Complementary and Alternative Medicine
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Figure 3: The HPLC chromatogram of fraction 6 with their retention time and area showing 4 major components.
Figure 4: Histopathology of liver, kidney, and spleen of Swiss mice treated with aqueous extract (1200mg/kg body weight orally). Liver (A),
kidney (B), and spleen (C): control; liver (D), kidney (E), and spleen (F): treated.Evidence-Based Complementary and Alternative Medicine 9
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Figure 5: Eﬀects of aqueous (AE) and methanol (ME) extracts
on the cotton-pellet-induced tissue granulation. DFD: diclofenac
disodium. White bars represent the granuloma weight while grey
bars showed percentage inhibition of granuloma weight. Values are
the mean ± S.E.M. of six rats. Statistical signiﬁcance is represented
by ∗P ≤ 0.05, ∗∗P ≤ 0.01, and ∗∗∗P ≤ 0.001, respectively
(unpaired Student’s t-test).
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Figure 6: Eﬀects of aqueous (AE) and methanol (ME) extracts on
the acetic-acid-induced vascular permeability in mice. The animals
were pretreated with various concentrations of the extract and
indomethacin (IND). Values are the mean ± S.E.M. of six mice.
Statisticalsigniﬁcanceisrepresentedby ∗P ≤ 0.05(Student’st-test).
the extract had no quenching eﬀect on the Griess reagent
at the concentrations used (Figure 8(a)). Furthermore, the
aqueous extract signiﬁcantly inhibited PGE2 (Figure 8(b))
and TNF-α production (Figure 8(c)) in a dose-dependent
manner and is more active than its alcoholic counterpart.
4.8. Eﬀect of Extract on IL-1β and IL-6 Production. To
investigatetheeﬀectofextractonLPS-inducedIL-1β andIL-
6 release, we estimated the level of these cytokines in extract-
treated THP-1 macrophages by enzyme immunoassay kits.
The results showed that the pretreating cells with extract
reduced both IL-1β a n dI L - 6p r o d u c t i o n( F i g u r e s9(a) and
9(b)) in concentration-dependent manner.
5. Discussion
In the Present study, we have evaluated, for the ﬁrst time,
theanti-inﬂammatoryandanalgesicactivityofbothaqueous
and methanol extracts of S. robusta young tender leaves,
used by two distinct tribes of India for ailments related to
inﬂammation and pain, in diﬀerent in vivo and in vitro
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Figure 7: Eﬀects of aqueous (AE) and methanol (ME) extracts on
membrane stabilization of hypotonic saline-induced human RBC,
in compare with indomethacin (IND). Values are the mean ±
S.E.M.ofsixsets.Statisticalsigniﬁcanceisrepresentedby ∗P ≤ 0.05,
and ∗∗P ≤ 0.01 (Student’s t-test).
model. Moreover, for the ﬁrst time, the proinﬂammatory
mediators NO and PGE2 and cytokines like TNF-α,I L - 1 β,
IL-6havebeenestimatedinpresenceorabsenceoftheextract
to know the possible mechanism of action.
The physicochemical standardization of collected sample
andextract(s)wasmadetoachievebetteryieldsandconstant
quality of the tested extracts [31]. The best quality sample
was selected on the basis of physicochemical and behavioral
properties, which showed that the post-rainy session sample
had the maximum yield (10.1 ± 0.51) with minimum water,
total ash, and acid insoluble ash content. The extraction was
done by standard protocol and followed by phytochemical
group tests and HPTLC analysis. The HPTLC proﬁle of
isolated fractions clearly reveals the signiﬁcant purity of
isolated fraction (Figures 2(a), 2(b), 2(c), 2(d), 2(e),a n d
2(f)). Friedelin was used as marker compound as the
preliminary phytochemical tests showed the presence of
triterpene and ﬂavonoids in the crude extract. Though the
isolated fraction (1–4) did not show friedelin (Figure 1),
the fractions 2 and 3 (Figures 2(d) and 2(e)) show that one
of the major components is very close to friedelin (parallel
blue lines). This result further indicates the possibility of
the presence of similar pharmacophores in Fractions 2-3,
while fractions 1 and 4 have diﬀerent proﬁle and contain
diﬀerent nature of compounds. Thus, the HPTLC studies
reveal preliminary information and warrant a detail study to
establish complete structure activity relationship to demon-
strated the biological signiﬁcance of isolated extract. How-
ever,theHPLCproﬁleofFraction6revealedfourmajorcom-
pounds. Earlier reports revealed that gum resin of S. robusta
containursolicacidandα-amyrenone[32,33],barkcontains
ursonic acid and oleanane [34], seed contains hopeaphenol,
leucoanthocyanidin,and3,7-dihydroxy-8-methoxyﬂavone7-
O-α-l-rhamnopyranosyl-(1→4)-α-l-rhamnonopyranosyl-
(1→6)-β-d-glucopy-ranoside [35], while heartwood con-
tains germacrene-D [10]. The isolation of β-amyrin, friedel-
in,β-sitosterol,pheophytin-α,anddihydroxyisoﬂavonefrom
mature leaves was also reported [36]. However, our pre-
liminary study indicated that the young tender leaf does not
contain friedelin.
Acute toxicity study over 14 days showed that the
extract possessed good safety proﬁle and the LD50 of the
orally fed methanol and aqueous extracts was 2.4–2.7gm/kg.10 Evidence-Based Complementary and Alternative Medicine
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Hence, for further study the dose was selected as 200 and
400mg/kg. In vivo toxicological study with aqueous extract
showed contrasting results, as the oral treatment did not
induce mortality or clinical toxicity, or any histopathological
changes in organs.
The acetic acid-induced writhing test indicated that the
numbersofwrithingmovementsweresigniﬁcantlylessinthe
treated mice, comparable to untreated group. The eﬀect of
the extract when compared to paracetamol, suggests that the
extract might have peripheral analgesic eﬀect. Furthermore,
the analgesic eﬀect produced by the tail ﬂick test was compa-
rable to that of morphine-treated control, suggesting central
analgesic eﬀect.
Acute inﬂammatory agent’s carrageenan and dextran
induce inﬂammation through diﬀerent mechanisms. Car-
rageenan, a standard phlogistic agent, is used to induce
paw edema in animals, as it is known to release histamine,
bradykinin, and serotonin (5-hydroxytryptamine) in the
early phase, and prostaglandins and kinin in the late
phase [37, 38], which induces protein rich exudates with
neutrophil at the site of inﬂammation resulting in increased
vascular permeability, and accumulation of ﬂuid in tissues
to form edema [39, 40]. The results of the carrageenan-
induced edema test revealed that extracts at 400mg/kg, in
3h p.o, have dose-dependent inhibitory eﬀect on edema
formation in both early and late phases, comparable to
diclofenac disodium. This suggests that the extract may
inhibit the synthesis and/or release of those mediators,
particularly the cyclooxygenase. Dextran is a high molecular
weight polysaccharide that induces anaphylactic reaction
characterized by extravasation and edema formation, as a
consequence of liberation of histamine and serotonin [23]
to the site of inﬂammation and the ﬂuid accumulation
through mast cell degradation [41]. Moreover, dextran can
cause inﬂammation by activating NF-κB and inducing the
expression of TLR-4, and proinﬂammatory cytokines IL-
1β,T N F - α and IL-6 in mice [42]. Thus, the inhibition of
dextran mediated edema by the extract was probably due to
the antihistaminic (inhibition of histamine and serotonin)
eﬀects of our extract. Furthermore, the decrease in the
cotton-pellet-inducedgranulomaweightbytheextractisdue
to the inhibition of proliferative phase of inﬂammation [22],
as the inﬂammatory response induced by the cotton pellet
can modulate the release of mediators leading to the tissue
proliferation and granuloma formation [43, 44]. The acetic-
acid-induced vascular permeability test is a typical capillary
permeability assay, used to further conﬁrm the antiinﬂam-
matory potential of the extract. The acetic acid is known to
cause dilation of arterioles and venules and increase vascular
permeability by releasing inﬂammatory mediators such as
histamine, prostaglandins, and leukotrienes by stimulating
mast cells [45]. During inﬂammation histamine, serotonin,
and other mediators increase vascular permeability, while
acetic acid causes an immediate sustained reaction [46].
Thus, the inhibition of acetic-acid-induced inﬂammation
suggests that the extracts may eﬀectively suppress the
exudative phase of acute inﬂammation.
Further, the protective eﬀect on hypotonic saline-
induced RBC lysis is an index of antiinﬂammatory activity
[47], which leads to the formation of free radical [48] that
cause secondary damage through lipid peroxidation [49, 50].
Thus, the compounds with membrane-stabilizing property
can protect the cell membrane against injurious substances
[27, 51] by interfering the release of phospholipases that
trigger the formation of inﬂammatory mediators [52]. Here,
the observed membrane stabilizing activity suggests that the
extract may inhibit the release of phospholipases and thereby
the formation of inﬂammatory mediators.
Toelucidatetheinvitromechanismofaction,theestima-
tion of proinﬂammatory mediators and cytokines, in pres-
ence or absence of the extract, was made in LPS-stimulated
THP-1 macrophage cells. Macrophages play a crucial role
in both nonspeciﬁc and acquired immune responses, and
its activation by LPS leads to a series of responses like
the production of proinﬂammatory cytokines (TNF-α,I L - 1 ,
IL-6) and activation of phospholipase A2 that produce
prostaglandin and NO [53]and, thus,canbe usedasa model
to test the potential antiinﬂammatory compounds [28]. Our
results demonstrated that the accumulation of nitrite in the
medium (due to enhanced NO production) takes place when
THP-1 macrophage was exposed to LPS for hour’s, and this
LPS-induced NO production was signiﬁcantly inhibited by
the aqueous extract in a time- and concentration-dependent
mannerwithoutnotablecytotoxicity.Thisinhibitioniseither
through the regulation of inducible nitric oxide (iNOS)
gene expression, or its direct interference with iNOS activity.
It is known that various anti-inﬂammatory drugs inhibit
prostaglandins (PGs) synthesis by cyclooxygenase (COX) 1
and 2. COX-1 provides a physiologic level of PGs, while
COX-2ishighlyinducedatinﬂammatorysites[54,55].Here,
the signiﬁcant inhibition of PGE2 production by the extract
is probably through COX-2 gene expression in LPS-treated
macrophages. However, further investigation is needed to
conﬁrm the extract action on NFκB activities.
Proinﬂammatory cytokines (TNF-α,I L - 1 β, and IL-6)
are known to control inﬂammation in vitro and in vivo
[56, 57] and are probably interlinked in a cascade, produced
by macrophages during inﬂammatory response. Moreover,
the development of hyperalgesia during inﬂammation is
probably mediated by proinﬂammatory cytokines [58].
Therefore, we have investigated the role of our extract in
cytokine production and found that the aqueous extract
signiﬁcantly reduced the production of TNF-α,I L - 1 β,a n d
IL-6 in dose-dependent manner. TNF-α plays a critical role
in both acute and chronic inﬂammation [59] by inﬁltration
of inﬂammatory cells through the adhesion of neutrophils
and lymphocytes [60], and stimulates neutrophils to release
cytokines(IL-1β andIL-6)andchemokines[61,62].Interac-
tionbetweenthesemediatorsenhancesfurtherinﬂammatory
reactions [63]. Thus, inhibition of TNF-α,I L - 1 β,a n dI L -
6 release can reduce the severity of inﬂammation. The
antichronic inﬂammatory activity of the extract observed
in cotton-pellet-induced granuloma model is further sup-
ported by this study, as cellular accumulations of ﬂuids and
proinﬂammatory cytokines were demonstrated within the
ﬁrst 14 days [64–66]. Therefore, the inhibition of tissue
granuloma by the extract, at least in part, is through the
interference with TNF-α,I L - 1 β, and IL-6 release. Thus,12 Evidence-Based Complementary and Alternative Medicine
the present study suggests that S. robusta young tender
leaf extract, particularly the aqueous extract, inhibits LPS-
induced iNOS and COX-2 protein expression, along with
NO2,P G E 2,a n dT N F - α production probably due to its
terpenoids, ﬂavonoids, or related compounds alone or in
combination, as reported with other plants [67–69], and
thereby it is useful in the prevention and treatment of
inﬂammatory conditions.
6. Conclusion
In conclusion, the observed analgesic and anti-inﬂammatory
activity of the aqueous extracts of S. robusta young leaves
might be through the inhibition of leukocyte activations
and reduced release of inﬂammatory mediators (PGE2,N O )
and proinﬂammatory cytokines (TNF-α, IL-1, and IL-6).
Therefore, our ﬁndings support the ethnomedicinal use of
S. robusta young leaves in the management of inﬂammatory
ailments via multilevel regulation of inﬂammatory reactions.
Additionally its low toxicity encourages clinical trials in pri-
mary health care after subchronic and chronic toxicological
studies with the active component(s).
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